Study S000948

A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02073929
Acronym: LIPT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 72
Start: 2014-03
Primary completion: 2015-12
Lead sponsor: Jens Faber
Conditions: Polycystic Ovary Syndrome; Cardiovascular Disease
Interventions: DRUG:Liraglutide for 26 weeks; DRUG:placebo
Results posted: TRUE

Registered primary outcomes

Change in Endogenous Thrombin Potential (ETP) [at time 0 and 26 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021441	Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Frøssing S, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28681988 DOI	cites ClinicalTrials.gov:NCT02073929; registry reference DERIVED:28681988